Open original FDA record ↗Recall record
- FDA identifier
- Z-1242-2016
- Company in FDA record
- Siemens Healthcare Diagnostics, Inc
- FDA record creation date
- Mar 24, 2016
- First observed by MedTech Watch
- Nov 16, 2026
- Latest observed content change
- Nov 16, 2026
- Recall classification
- Class II
Reason stated in the source
The drug fulvestrant (Faslodex) may cause falsely elevated estradiol results.
Source facts
- Action
- Siemens issued an Urgent Medical Device Correction (UMDC) to affected Siemens Healthcare Diagnostics customers in the United States on January 13, 2016 to be delivered to customers on January 14, 2016 via Federal Express. An Urgent Field Safety Notice (UFSN) was sent out for distribution to all customers outside the United States on January 13, 2016. The letters identified affected product, problem and the actions to be taken. Customers may continue to use the estradiol assays to report patient results however, the assays should not be used for patients being treated with fulvestrant. Customers where instructed to complete and return the Correction Effectiveness Check attached. For questions contact your Siemens Customer Care Center or your local Siemens technical support representative.
- Initiated
- 2016-01-13
- Root cause
- Device Design
- Terminated
- 2018-01-08
- Distribution
- Worldwide Distribution US Nationwide , AR, AU, AU, BD, BO, BR, CA, CH, CL, CN, CO, DO, EC, EG, HK, ID, IE, IL, IN, JP, KR, LK, LY, MX, MY, NI, NP, NZ, PE, PH, PY, SA, SG, SV, TH, TW, UY, VE, VN, and ZA.
- Recall number
- Z-1242-2016
- Recall status
- Terminated
- CDRH record ID
- 143008
- FDA record created
- 2016-03-24
- Recall event number
- 73052